AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03405441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: All participants will receive matching placebo orally in Part 1 and Part 2 of the study.
Study NCT03405441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55375515
Description: Participants will receive JNJ-55375515 as per the assigned treatment in Part 2.
Study NCT01593306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, Cisplatin
Description: intravenous paclitaxel infusion at 50mg/m2/week and cisplatin at 30mg/m2/week for 5 weeks. if supplement Chemo Radiotherapy is required then similar dose per week for 2 more weeks.
Study NCT01593306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: intravenous infusion of cisplatin 40mg/m2/week for 5 weeks. if I/C Brachytherapy is not feasible then supplement CRT given with similar dose of cisplatin for 2 more cycles.
Study NCT01155375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Experimental: Ferumoxytol
Study NCT01155375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Iron
Description: Active Comparator: Oral iron
Study NCT04335812 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based Cognitive Behavior Therapy
Description: The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.
Study NCT04335812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive Behavior Therapy
Description: The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.
Study NCT01166321 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon Ion Radiotherapy
Description: Carbon Ion Boost 18 Gy E in single Fractions of 3 Gy E
Study NCT04520360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carisbamate
Description: Carisbamate is currently under investigation as an adjuvant antiepileptic therapy in Lennox-Gastaut patients. Lennox-Gastaut syndrome (LGS) is a rare and highly debilitating form of childhood epilepsy that typically is diagnosed between 2 and 8 years of age, with peak onset at 3 to 5 years of age, and frequently persists into adulthood. Treatment options are limited and complicated by the multiple seizure types associated with LGS. Given the breadth of physical and cognitive disabilities associated with LGS, the development of antiseizure medications with appropriate oral dosing forms is needed to ensure administration feasibility and compliance in the target population.
Study NCT01295034 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: conventional vitamin D treatment
Description: Subjects in Protocol A (the conventional/active placebo arm) will receive 50,000 IU/wk of vitamin D2 for 8 wk followed by 1000 IU/d of vitamin D3 for 48 wk.
Study NCT01295034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiered/titrated vitamin D dosing
Description: Subjects in Protocol B will receive 2000-4000 IU/d of vitamin D3, depending on the basal 25(OH)D level, with dose titration, as necessary, based on the slope of the initial response, for a total duration of treatment of 12 mo.
Study NCT03249714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Provided in pre-filled syringes for subcutaneous injection (s.c.) administration containing 20 mg ofatumumab (50 mg/mL, 0.4 mL content)
Study NCT03249714 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo of ofatumumab
Description: Matching placebo in pre-filled syringes
Study NCT02634346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALK3831
Description: Daily dosing
Study NCT02634346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Daily dosing
Study NCT02634346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dosing
Study NCT03917680 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Factor XII dosage
Description: Factor XII (FXII, Hageman factor) will be measured in plasma. It is converted to FXIIa by an activator. The FXIIa protease cleaves a chromogenic substrate and releases p-nitroaniline (pNA), which can be measured photometrically.
Study NCT03917680 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: p.Thr328Lys mutation detection
Description: Sequencing of exon 9 of franking introns of FXII, for identification of the p.Thr328Lys mutation.
Study NCT03917680 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Videocapillaroscopy
Description: It is an optical method to visualize the most superficial part of the cutaneous microcirculatory network. It provides morphological information.
Study NCT03917680 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Videocapillaroscopy
Description: It is an optical method to visualize the most superficial part of the cutaneous microcirculatory network. It provides morphological information.
Study NCT00802425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM-111
Description: single intratympanic injection
Study NCT00802425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single intratympanic injection
Study NCT01944813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACp conversation
Description: Intervention: Advance Care Planning conersation between a healtprofessionel and a patient about end-of-life discussions.
Study NCT03486457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: tablets, 5 mg BID x 6 months
Study NCT03486457 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets, to match tofacitinib 5 mg BID x 3 months
Study NCT03486457 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tofacitinib
Description: tablets, 5 mg BID x 3 months
Study NCT01378923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REVAMP
Description: The Re-entry values and mindfulness program (REVAMP) is an 8 session group intervention designed for jail inmates nearing release into the community
Study NCT01378923 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: TAU
Description: have access to standard jail programs and services
Study NCT04227964 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative, bone replacement graft, barrier membrane
Study NCT04227964 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth extraction and replacement
Study NCT03306836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin Sodium
Description: Infused with 5000 IU of Heparin Sodium
Study NCT03306836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin Sodium
Description: Infusion Heparin Sodium at a rate of 18 IU / kg.h
Study NCT03306836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin Sodium
Description: Infusion Heparin Sodium at a rate of 18 IU / kg.h
Study NCT00852046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: IV solution, 0.2 mcg/kg/hr or 0.6 mcg/kg/hr for a max of 5 days
Study NCT00852046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine
Description: IV solution, 0.2 mcg/kg/hr or 0.6 mcg/kg/hr for a max of 5 days
Study NCT02989597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Perioperative anesthesia medication
Study NCT02989597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Perioperative anesthesia medication
Study NCT02989597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Perioperative pain medication
Study NCT02989597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Perioperative pain medication
Study NCT02989597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Perioperative pain medication
Study NCT02989597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Perioperative pain medication
Study NCT02868632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: anti-PD-L1 human monoclonal antibody
Study NCT02868632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: anti-CTLA4 human monoclonal antibody
Study NCT02868632 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Stereotactic body radiation therapy (SBRT) will be administered at the standard dose of 6 Gy daily for 5 days.
Study NCT04663009 — intervention group
Intervention type: DEVICE
Intervention: AutoPulse
Description: A band circumflex of the chest that provide chest cage compressions.
Study NCT02928042 — intervention group
Intervention type: OTHER
Intervention: Lactobacillus bacteria
Description: Antimicrobial effects of Lactobacillus bacteria (LAB) and nisin bacteriocin on pathogen bacteria and commercial strains of the same bacteria's growth rate will be investigated.
Study NCT00533117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Fluoxetine is administered in standard dosing 20, 40, 60, 80 mg increased monthly if tolerated
Study NCT00533117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy
Description: Dialectical Behavior Therapy is a form of CBT originally developed to treat suicidal and self injuring individuals with borderline personality disorder. Treatment consists of 2 sessions/week: individual psychotherapy and skills training group.
Study NCT00533117 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Dialectical Behavior Therapy
Description: Dialectical Behavior Therapy is a form of CBT originally developed to treat suicidal and self injuring individuals with borderline personality disorder. Treatment consists of 2 sessions/week: individual psychotherapy and skills training group.
Study NCT00533117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy
Description: Supportive therapy is a manualized form of psychotherapy designed to enhance individual's strengths and coping mechanisms while reducing distress.
Study NCT00533117 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive psychotherapy
Description: Supportive therapy is a manualized form of psychotherapy designed to enhance individual's strengths and coping mechanisms while reducing distress.
Study NCT00419406 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UVA1 phototherapy
Study NCT00419406 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NB-UVB phototherapy
Study NCT05973032 — intervention group
Intervention type: OTHER
Intervention: MRD
Description: Calculate the 3-year EFS based on the MRD status (MRD positive and negative groups)
Study NCT01107054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00610355
Description: An orally inhaled dose of PF-00610355 450 µg on days 1 to 4
Study NCT01107054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00610355
Description: An orally inhaled dose of PF-00610355 1200 µg on days 1 to 4
Study NCT01107054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: A single oral dose of moxifloxacin 400 mg on Day 4.
Study NCT01107054 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A single oral dose of non-matched placebo on Day 4.
Study NCT00823017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-preferred music
Description: Music of patients' preference
Study NCT00823017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation Music
Description: Relaxation music compiled from results of first three stages of study
Study NCT00823017 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care Environment
Description: Control, no interventions
Study NCT03449667 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoneurolysis
Description: Cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. For active probes, the nitrous oxide will be deployed to the tip where a drop in temperature to -70°C will result in cryoneurolysis.
Study NCT03449667 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cryoneurolysis
Description: Cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. For active probes, the nitrous oxide will be deployed to the tip where a drop in temperature to -70°C will result in cryoneurolysis.
Study NCT03449667 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Comparator
Description: Sham cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. However, for sham probes, the nitrous oxide is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis.
Study NCT01553305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised high-intensity exercise programme
Description: Six-weeks supervised high-intensity muscle strength training and physical fitness with training sessions twice a week followed by 6-weeks unsupervised high-intensity exercise programme.
Study NCT03449667 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Sham cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. However, for sham probes, the nitrous oxide is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis.
Study NCT01743222 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: eASC
Description: * First cohort: Intra lymph node injection of 2.5 millions of eASCs suspended in 0.5 ml of HypoThermosol per lymph node, total dose 5 millions of cells.~* Second cohort: Intra lymph node injection of 5 millions of eASCs suspended in 0.25 ml of HypoThermosol per lymph node, total dose 10 millions of cells.
Study NCT01743222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * First cohort (2 volunteers): injection of 0.25 ml of HypoThermosol (HTS) per lymph node~* Second cohort (2 volunteers): injection of 0.5 ml of HypoThermosol (HTS) per lymph node
Study NCT04252534 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PRP combined Magnovision
Description: The rEMS helmet is used to stimulate the retina and visual pathways. (MagnovisionTM) combined with subtenon platelet rich plasma injection
Study NCT04252534 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP
Description: Fresh autologous platelet rich plasma, injected subtenon space.
Study NCT00288132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: A 12-month diabetes self-management intervention delivered via telemedicine, with opportunity to receive telemedicine-based screening eye exam, was conducted.
Study NCT00288132 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Upon randomization, received one 15-minute diabetes self-management individual session, using American Diabetes Association materials. Continued care, as usual, from their primary care provider throughout duration of active 12 month intervention period.
Study NCT01096875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 40mg/day once daily for two weeks prior to surgery
Study NCT01096875 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1tb/day once daily for two weeks prior to surgery
Study NCT01028820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: 8 weeks, starting dosage 5mg titrating up 5mg every week as needed to maximum dosage of 25mg daily
Study NCT02788552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiamine Hydrochloride
Description: Administered Intravenously in 100ml bag of normal saline (0.9%) infused over 30 mins.
Study NCT04210531 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BJ) acute supplementation
Description: One serving 140 mL of BJ (12.8 mmol of NO3-; Beet-It-Pro Elite Shot, James White Drinks Ltd., Ipswich, UK) after an overnight fast and 3 h before initiating the testing session.
Study NCT04210531 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo acute supplementation
Description: One serving placebo drink (0.08 mmol of NO3-; Salud Viva, Nano Salud 32 S.L) after an overnight fast and 3 h before initiating the testing session.
Study NCT01523366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Min - 90mg/Max - 180mg tablets (loading dose)
Study NCT01553305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise programme
Description: Supervised exercise programme
Study NCT00562705 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: growth hormone- Genotropin or NorditropinSimplex and nutritional intervention
Description: A combined treatment of growth hormone (Genotropin or NorditropinSimplex or Biotropin) and nutritional intervention
Study NCT01523366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 75mg (once daily)/Max - 600mg tablets (loading dose)
Study NCT04128852 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MagnetOs Putty
Description: MagnetOs Putty has a CE-mark (2115660CE01) as well as FDA 510(k) clearance (K171563/K181958).
Study NCT01067053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab, capecitabine, oxaliplatin
Description: 6 cycles (3 weeks each one) of:~* bevacizumab: 7,5 mg/kg (iv), 1st day of each cycle.~* capecitabine: 1000 mg/m2 bid, oral. Days: 1-14 every three weeks.~* oxaliplatin: 130/mg/m2(iv),1st day of each cycle.~After the first 6 cycles of treatment, continuing only with bevacizumab and capecitabine
Study NCT00562705 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: growth hormone-Genotropin or NorditropinSimplex or Biotropin
Description: Growth hormone treatment (Genotropin, or NorditropinSimplex or Biotropin).
Study NCT02960854 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT03879837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate pressurized metered dose inhaler
Description: 110 mcg per actuation
Study NCT03879837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flovent HFA pressurized metered dose inhaler
Description: 110 mcg per actuation
Study NCT03879837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pressurized metered dose inhaler
Description: no active content
Study NCT00093808 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Study NCT00093808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT00093808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Study NCT01809223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conbercept, Fixed
Description: intravitreal injection of 0.5 mg conbercept per month, fixed injection
Study NCT01809223 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: conbercept, Fixed
Description: intravitreal injection of 0.5 mg conbercept per month, fixed injection
Study NCT01809223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conbercept, PRN
Description: intravitreal injection of 0.5 mg conbercept as need, PRN
Study NCT01809223 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: conbercept, PRN
Description: intravitreal injection of 0.5 mg conbercept as need, PRN
Study NCT01809223 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham injection
Description: sham intravitreal injection per month, fixed injection
Study NCT03098420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2mg Dexamethasone
Description: 0.5 mL (2mg) of dexamethasone and 0.5 ml of normal saline
Study NCT03098420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4mg Dexamethasone
Description: 1 mL (4mg) of dexamethasone
Study NCT03098420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine (TAP blocks)
Description: 20mL of 0% ropivacaine with 20mL of 0.5% ropivacaine